About this trial
The goal of the study is to check efficacy of probiotics in preventing necrotizing enterocolitis. The main questions would be if the preterm baby developed NEC or not.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male and female preterm infants with a gestational age less than 35 weeks.
All indoor patients and outdoor patients who present within 24hrs of birth
Disqualifiers
• Infants with congenital or developmental gastrointestinal disorders for example omphalocele, malrotation, gastroschisis.
Infants with severe sepsis or gastrointestinal bleeding on presentation
Trial design
Parallel
Treatments tested in this trial
Probiotic
DrugAll preterm babies \<34 weeks Gestational age admitted within 24 hrs of life will be eligible for the study. Those full filling inclusion criteria and consenting to participate will be recruited. Consent will be obtained by team not caring for the patient. Each recruited patient will be assigned a case ID number. Based on the Randomization babies will be assigned to either the intervention group or control group. Study group: Multistrain probiotic containing a mix of Lactobacillus and Bifidobacterium spp. * Dose is 1 million international units (0.2ml or 5 drops) OD * Started as soon as feed is in initiated
10% dextrose
DrugThis will receive 10% DW as placebo
Treatment groups
Trial outcomes
Primary outcomes
Number of participants who develop NEC on probiotic vs placebo
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: